

Pre-IPO Coverage: Change Healthcare (CHNG)

Change Healthcare (CHNG), a healthcare software platform, is expected to IPO on Thursday, June 27. At a price range of \$16-\$19 per share, the company plans to sell up to \$700 million in common stock and an additional \$250 million in tangible equity units. At the midpoint of the IPO price range, CHNG will have an expected market cap of \$5.2 billion and currently earns our <u>Attractive rating</u>.

Even if you're not familiar with CHNG, there's a good chance you've interacted with the company. CHNG facilitated 14 billion healthcare transactions with a total value of ~\$1 trillion last year, or roughly 1/3 of all U.S. healthcare expenditures. Their customer base includes over 900,000 physicians, and they transact clinical records for over 112 million patients. In other words, the company has become an integral part of the U.S. healthcare system.


This report aims to help investors sort through Change Healthcare's financial filings to understand the fundamentals and valuation of this IPO.

Get the best fundamental research


GAAP Earnings Mislead Investors

CHNG was founded in 2017 through a joint venture between Nashville-based Change Healthcare (formerly HCIT Holdings) and the Technology Solutions segment of McKesson Corporation (MCK). CHNG is a holding company that has no assets aside from its interest in the joint venture.

At first glance, CHNG appears to be growing rapidly. GAAP net income increased from \$192 million in 2017 to \$234 million in 2018, or 22% year-over-year (YoY). However, CHNG's <u>economic earnings</u> – the true cash flows of the business – actually declined from \$257 million to \$243 million, or -5% YoY. See Figure 1.



GAAP Earnings Mislead Investors



Sources: New Constructs, LLC and company filings

A variety of factors – integration costs, new accounting rules, tax reform, and the sale of its Extended Care business, among others – distort CHNG's reported earnings. In both years, the company incurred significant integration and restructuring costs that make reported earnings lower than economic earnings. The biggest items contributing to the increase in GAAP net income for 2018 are:

- \$38 million in severance costs that decreased earnings in 2017
- A <u>\$111 million</u> gain on sale that increased earnings in 2018

Page 1 of 6

Important Disclosure Information is contained on the last page of this report. The recipient of this report is directed to read these disclosures.



These items are partially offset by:

- A <u>\$50 million</u> accretion gain that increased earnings in 2017
- A <u>\$35 million</u> gain from tax reform that increased earnings in 2017

The decrease in economic earnings, on the other hand, can be entirely attributed to the increase in CHNG's weighted average cost of capital (<u>WACC</u>) from 6.1% in 2017 to 6.4% in 2018. Net operating profit after tax (<u>NOPAT</u>) and <u>invested capital</u> – the two other components of economic earnings – both changed by less than 1% from 2017 to 2018.

Stable Cash Flows

The minimal change in CHNG's NOPAT and invested capital suggests that the cash flows of this business should be fairly stable going forward. In addition, 88% of the company's sales come from recurring revenue, and the business had a 100% retention rate for its top 50 payer customers and its top 50 provider customers in 2018.

As a result of this high retention rate, we would expect CHNG's cash flows to grow in-line with U.S. healthcare spending over the long term. U.S. per capita healthcare spending has grown by 6% compounded annually since 1970 and never had a year-over-year decline in that time period, according to data from <u>Peterson-Kaiser</u>. The Center for Medicare and Medicaid Services projects U.S. healthcare spending will <u>continue to grow at ~6%</u> annually over the next decade.

On the other hand, this steady rise in healthcare costs has led to increasing calls for reform of the healthcare system, including <u>Medicare for All</u> plans that would abolish private insurance. A reform on this scale would put many of CHNG's customers out of business and significantly alter the company's business.

As a result, investors must model significant uncertainty when analyzing CHNG. If the healthcare system stays more or less the same, the company should experience consistent growth in cash flows. If, however, there is significant governmental reform, it could impact the company in a massive (and unpredictable) manner.

Public Shareholders Have No Rights

As with many other recent IPO's, CHNG gives public shareholders no say in the governance of the company. However, CHNG locks out public shareholders from governance through a different method than the standard dual-class share structure. The company that is going public, CHNG, is a holding company with no assets aside from its economic interest in the joint venture created by McKesson and Change Healthcare. The joint venture itself, which runs the operations of the company, is controlled by these two partners, with McKesson having 70% control.


As a result, investors that buy shares in CHNG will have no ability to hold management accountable, or to stop the company from operating in a way that might benefit McKesson at the expense of shareholders.


ROIC Regression Reveals Shares Are Undervalued

<u>Numerous case studies</u> show that getting ROIC right is an important part of making smart investments. This <u>paper</u> compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up. The technology that enables this research is featured by <u>Harvard Business School</u>.

Per Figure 2, ROIC explains 50% of the difference in valuation for the 21 payment-focused software companies CHNG lists as peers in its S-1. CHNG trades at a discount to peers as shown by its position below the trend line.







ROIC Analysis Reveals CHNG Is Undervalued

Sources: New Constructs, LLC and company filings

If the stock were to trade at parity with its peer group, it would be worth \$45/share, a 155% upside to the midpoint of the IPO range. CHNG's valuation implies that its ROIC will decline from 11% to 3%.

DCF Model Reveals Potential Upside

At the midpoint of its IPO range, \$17.50/share, CHNG has a price to economic book value (<u>PEBV</u>) ratio of 1.2. This ratio means the market expects CHNG to grow NOPAT by no more than 20% for the remainder of its corporate life. Given the high historical growth rate of healthcare spending, this expectation seems pessimistic.

Our reverse discounted cash flow (DCF) model quantifies the potential upside from CHNG's cheap valuation.

If CHNG can maintain 2018 NOPAT margins of 18% and grow NOPAT by 3% compounded annually for the next decade, the stock is worth ~\$23/share today, a 29% upside from the midpoint of the IPO range. <u>See the math behind this dynamic DCF scenario</u>.

Even if investors believe CHNG will grow at just half the rate of the overall healthcare industry, the stock still has significant potential upside.

Critical Details Found in Financial Filings by Our <u>Robo-Analyst Technology</u>

As investors <u>focus more</u> on fundamental research, research automation technology is needed to analyze all the critical financial <u>details in financial filings</u>. Below are specifics on the adjustments¹ we make based on Robo-Analyst² findings in Change Healthcare's S-1:

Income Statement: we made \$625 million of adjustments, with a net effect of removing \$356 million in <u>non-operating expense</u> (11% of revenue). You can see all the adjustments made to CHNG's income statement <u>here</u>.

Balance Sheet: we made \$229 million of adjustments to calculate invested capital with a net increase of \$147 million (3% of net assets). You can see all the adjustments made to CHNG's balance sheet <u>here</u>.

Valuation: we made \$5.1 billion of adjustments with a net effect of decreasing shareholder value by \$5.1 billion. You can see all the adjustments made to CHNG's valuation <u>here</u>.

¹ This <u>paper</u> compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up. ² Harvard Business School Features the powerful impact of research automation in the case study <u>New Constructs: Disrupting Fundamental</u> <u>Analysis with Robo-Analysts</u>.



This article originally published on <u>June 25, 2019</u>.

Disclosure: David Trainer, Kyle Guske II, and Sam McBride receive no compensation to write about any specific stock, style, or theme.

Follow us on <u>Twitter</u>, <u>Facebook</u>, <u>LinkedIn</u>, and <u>StockTwits</u> for real-time alerts on all our research.



New Constructs[®] - Research to Fulfill the Fiduciary Duty of Care

Ratings & screeners on 3000 stocks, 450 ETFs and 7000 mutual funds help you make prudent investment decisions.

New Constructs leverages the latest in machine learning to analyze structured and unstructured financial data with unrivaled speed and accuracy. The firm's forensic accounting experts work alongside engineers to develop proprietary NLP libraries and financial models. Our investment ratings are based on the best fundamental data in the business for stocks, ETFs and mutual funds. Clients include many of the top hedge funds, mutual funds and wealth management firms. David Trainer, the firm's CEO, is regularly featured in the media as a thought leader on the fiduciary duty of care, earnings quality, valuation and investment strategy.

To fulfill the Duty of Care, research should be:

- 1. **Comprehensive** All relevant publicly-available (e.g. 10-Ks and 10-Qs) information has been diligently reviewed, including footnotes and the management discussion & analysis (MD&A).
- 2. **Un-conflicted** Clients deserve unbiased research.
- 3. **Transparent** Advisors should be able to show how the analysis was performed and the data behind it.
- 4. **Relevant** Empirical evidence must provide <u>tangible, quantifiable correlation</u> to stock, ETF or mutual fund performance.

Value Investing 2.0: Diligence Matters: Technology is Key to Value Investing With Scale

Accounting data is only the beginning of fundamental research. It must be translated into economic earnings to truly understand profitability and valuation. This translation requires deep analysis of footnotes and the MD&A, a process that our <u>robo-analyst technology</u> empowers us to perform for thousands of stocks, ETFs and mutual funds.



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.